S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Price:
289.4
CNY
-0.89%
Market Closed
Market Cap:
¥119.5B
Relative Value
The Relative Value of one Sichuan Biokin Pharmaceutical Co Ltd stock under the Base Case scenario is 24.65 CNY. Compared to the current market price of 289.4 CNY, Sichuan Biokin Pharmaceutical Co Ltd is Overvalued by 91%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
24.65
CNY
Overvaluation 91%
S
Multiples Across Competitors
Competitors Multiples
Sichuan Biokin Pharmaceutical Co Ltd Competitors
Sichuan Biokin Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
119.5B CNY | 53.7 | -140.2 | -144.2 | -144.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
990.8B USD | 15.2 | 48 | 32.3 | 34.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.6B USD | 6.3 | 22 | 15.3 | 18.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
285.8B CHF | 4.7 | 30.6 | 12.9 | 15.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232.4B GBP | 5.4 | 31 | 17.1 | 24.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
238.6B CHF | 5.5 | 22 | 13.6 | 17.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
298.8B USD | 4.6 | 16.3 | 10.2 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.5 | 13.5 | 9.9 | 11.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
157.2B USD | 2.5 | 20.2 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.1B USD | 2.5 | 17.3 | 6.8 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
